Eosinophilic pustular folliculitis (EPF) was originally described by Ofuji in 1965 with the first case presenting as folliculocentric pustules distributed on the face, torso, and arms of a Japanese female. Since the initial description, three distinct subtypes of EPF now exist. These types include the originally described classic variant seen in the Japanese population, an immunosuppressed (EPF-IS) variant, and a rare infantile form.
All three subtypes of EPF are more commonly seen in men compared to women. The classic form has a peak incidence between the third and fourth decades. It presents as recurrent follicular papules and pustules located on the face, trunk, or extremities and more rarely the palmoplantar surfaces. Post inflammatory hyperpigmentation is common and leukocytosis with eosinophilia is seen in up to 35% of patients.
The IS subtype demonstrates intensely pruritic discrete erythematous follicular papules with palmoplantar sparing, and infrequent annular or circinate plaque forms. Frequently with the IS-HIV form, CD4 cell counts are below 300 cells/μl (500-1200 cells/μl) and 25%-50% of patients have lymphopenia with eosinophilia. The IS-Heme form has been predominantly associated with hematologic malignancies including non-Hodgkin lymphoma, leukemia (ALL and AML), and myelodysplastic syndrome. For all of these cases except two, EPF followed bone marrow transplant, peripheral blood stem cell transplant, or chemotherapy initiation. To date, no reported cases of EPF presenting prior to the diagnosis of mantle cell lymphoma have been described.
Our patient cases represent variants of immunosuppression related eosinophilic pustular folliculitis. Patient A presented initially with EPF a month before being diagnosed with mantle cell lymphoma. Patient B had a more diffuse clinical presentation secondary to his underlying chronic immunosuppression.
Histopathologically, all three identified forms of EPF show acute and chronic lymphoeosinophilic infiltrate concentrated at the follicular isthmus. In addition, scattered mononuclear cells, eosinophils, and neutrophils are typically found within the pilar outer root sheath, sebaceous glands, and ducts. Follicular mucinosis is seen in up to 40% of cases as well as follicular destruction.
The pathophysiology is believed to represent a Th2 predominant pathway (IL-3, IL-5, and IL-13) with eotaxin-3 expression, which promote eosinophil recruitment, inflammation, and tissue damage seen in EPF.
Multiple therapeutic modalities have been reported for the treatment of EPF. For all three types, moderate to high potency topical corticosteroids are considered first line of therapy while UVB phototherapy 2-3 times weekly remains the gold standard treatment. Indomethacin (50-75mg/ day) is first line treatment for classic EPF due to its ability to limit the chemoattraction of eosinophils. Other potential treatments include prednisone, psoralen plus UVA, cetirizine, metronidazole, minocycline, itraconazole, dapsone, systemic retinoids, topical tacrolimus, and topical permethrin. History of Present Illness: Patient was admitted to the hospital for lower extremity deep vein thrombosis (DVT) in addition to a six-month history of a diffuse pruritic rash on his head, neck, trunk, and proximal extremities. Skin biopsy performed 3 months prior was consistent with a spongiotic drug reaction. However the skin rash did not improve after adjusting his medications. He describes the rash as stable and does admit to slight improvement with topical triamcinolone use at home.
Medical History/Surgical History: Chronic kidney disease s/p renal transplant with chronic allograft nephropathy and episodes of acute graft rejection, history of upper and lower extremity DVTs, hypertension, anemia of chronic disease, congestive heart failure, chronic atrial fibrillation, morbid obesity, and chronic immunosuppression Laboratory Data: CBC: hemoglobin 11(13.5-18 g/dL) hematocrit 35 (40-54%) wbc 16 (4.5-11 thou/cmm), absolute eosinophils 9 (0-0.5 thou/cmm), eosinophils 54% (0-4%), creatinine 2.9 (0.7-1.5 mg/dL), GFR 22 (>60), UA wnl, sirolimus and tacrolimus drug levels wnl, serum HIV negative, negative for translocation (9:22) and BCR/ABL transcript product 
